Evaluation of factor Va from the venom of the Australian Brown snake as a topical and systemic anti-bleeding agent [ 2008 - 2008 ]

Research Grant

Researchers: Prof Martin Lavin (Principal investigator) ,  Dr Paul Masci ,  E/Pr John De Jersey

Brief description Anti-bleeding agents are important pharmaceuticals for use in truama, surgery and several medical conditions to reduce blood loss and the need for blood transfusion. Some Australian snakes contain in their venom a powerful blood clotting agent. This agent mimics the human clotting machinery. In this project, we plan to test purified components of snake venom for an ability to clot human blood. We will undertake laboratory test-tube experiments as well as using an animal model after ethical approval. This project seeks to capture some of the genetic blueprint of an Australian snake, for human benefit by developing a new therapeutic agent based on a venom component. If the experiments are successful, the next stage will be further testing of efficacy and toxicity before seeking approval for clinical trials. The research is supported by the Australian pharmaceutical company QRx Pharma Pty Ltd who will work with Uniquest Pty Ltd to protect intellectual property generated in the project.

Funding Amount $AUD 113,742.60

Funding Scheme NHMRC Development Grants

Notes Development Grant